<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <schemaVersion>X0202</schemaVersion>
<headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001729510-26-000009</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001729510</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.0001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>09/30/2026</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001802369</issuerCik>
        <issuerName>ADARx Pharmaceuticals, Inc.</issuerName>
        <issuerCusips>
          <issuerCusipNumber>00654F105</issuerCusipNumber>
        </issuerCusips>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">5871 Oberlin Drive, Suite 200</street1>
          <city xmlns="http://www.sec.gov/edgar/common">San Diego</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">CA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">92121</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Zhen Li</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>4939795.00</soleVotingPower>
        <sharedVotingPower>5861199.00</sharedVotingPower>
        <soleDispositivePower>4939795.00</soleDispositivePower>
        <sharedDispositivePower>5861199.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>10800994.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>9.6</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) Amount reported in Row (9) consists of (i) 4,939,795 shares of Common Stock (as defined herein) subject to options held by Dr. Li that are exercisable within 60 days of September 30, 2026 and (ii) 5,861,199 shares of Common Stock held by the Titanium Boulder Irrevocable Trust dated July 11, 2020 (the "Titanium Trust"), for which Dr. Li and Zhiqing Zhou, her spouse, serve as trustees. Dr. Li and her spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust.

(2) Percent of class represented by amount in Row (11) is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026, and (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by Dr. Li within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Explanatory Note: This Amendment No. 1 amends the Schedule 13G originally filed by Zhen Li on November 13, 2026 to add her spouse, Zhiqing Zhou, and Zhen Li and Zhiqing Zhou, as co-trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020, as reporting persons. This Amendment No. 1 also revises the aggregate amount beneficially owned by Zhen Li to exclude 50,564 shares of Common Stock issuable upon exercise of options held by Zhiqing Zhou that are exercisable within 60 days of September 30, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Zhiqing Zhou</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>50564.00</soleVotingPower>
        <sharedVotingPower>5861199.00</sharedVotingPower>
        <soleDispositivePower>50564.00</soleDispositivePower>
        <sharedDispositivePower>5861199.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>5911763.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.5</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>(1) Amount reported in Row (9) consists of (i) 50,564 shares of Common Stock subject to options held by Mr. Zhou that are exercisable within 60 days of September 30, 2026 and (ii) 5,861,199 shares of Common Stock held by the Titanium Trust, for which Mr. Zhou and his spouse, Zhen Li, serve as trustees. Mr. Zhou and his spouse, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust.

(2) Percent of class represented by amount in Row (11) is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026 and (ii) 50,564 shares of Common Stock issuable upon exercise of options held by Mr. Zhou within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Exchange Act.

Explanatory Note: This Amendment No. 1 amends the Schedule 13G originally filed by Zhen Li on November 13, 2026 to add her spouse, Zhiqing Zhou, and Zhen Li and Zhiqing Zhou, as co-trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020, as reporting persons. This Amendment No. 1 also revises the aggregate amount beneficially owned by Zhen Li to exclude 50,564 shares of Common Stock issuable upon exercise of options held by Zhiqing Zhou that are exercisable within 60 days of September 30, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Zhen Li and Zhiqing Zhou, as Co-Trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020</reportingPersonName>
      <citizenshipOrOrganization>CA</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <sharedVotingPower>5861199.00</sharedVotingPower>
        <sharedDispositivePower>5861199.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>5861199.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.5</classPercent>
      <typeOfReportingPerson>OO</typeOfReportingPerson>
      <comments>(1) Amount reported in Row (9) consists of 5,861,199 shares of Common Stock held by the Titanium Trust, for which Dr. Li and Mr. Zhou serve as trustees.

(2) Percent of class represented by amount in Row (11) is based on 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026.

Explanatory Note: This Amendment No. 1 amends the Schedule 13G originally filed by Zhen Li on November 13, 2026 to add her spouse, Zhiqing Zhou, and Zhen Li and Zhiqing Zhou, as co-trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020, as reporting persons. This Amendment No. 1 also revises the aggregate amount beneficially owned by Zhen Li to exclude 50,564 shares of Common Stock issuable upon exercise of options held by Zhiqing Zhou that are exercisable within 60 days of September 30, 2026.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>ADARx Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>5871 Oberlin Drive, Suite 200, San Diego, CA 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Zhen Li
Zhiqing Zhou
Zhen Li and Zhiqing Zhou, as Co-Trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The principal business address of each person named in Item 2(a) is c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Zhen Li is a citizen of the United States.
Zhiqing Zhou is a citizen of the United States.
The Titanium Trust is subject to and governed by the laws of the State of California</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>As of September 30, 2026, Zhen Li may be deemed the beneficial owner of 10,800,994 shares of Common Stock, $0.0001 par value per share (the "Common Stock"). This amount consists of (i) 4,939,795 shares of Common Stock subject to options held by Dr. Li that are exercisable within 60 days of September 30, 2026 and (ii) 5,861,199 shares of Common Stock held by the Titanium Trust, for which Dr. Li and Mr. Zhou serve as trustees. Dr. Li and Mr. Zhou, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust.

As of September 30, 2026, Zhiqing Zhou may be deemed the beneficial owner of 5,911,763 shares of Common Stock. This amount consists of (i) 50,564 shares of Common Stock subject to options held by Mr. Zhou that are exercisable within 60 days of September 30, 2026 and (ii) 5,861,199 shares of Common Stock held by the Titanium Trust, for which Mr. Zhou and Dr. Li serve as trustees. Mr. Zhou and Dr. Li, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust.

As of September 30, 2026, the Titanium Trust may be deemed the beneficial owner of 5,861,199 shares of Common Stock. This amount consists of 5,861,199 shares of Common Stock held by the Titanium Trust, for which Dr. Li and Mr. Zhou serve as trustees. Dr. Li and Mr. Zhou, as trustees of the Titanium Trust, share voting and dispositive power with respect to the securities held by the Titanium Trust.</amountBeneficiallyOwned>
        <classPercent>As of September 30, 2026, Zhen Li may be deemed to beneficially own approximately 9.6% of the shares of Common Stock outstanding. The foregoing percentage is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026 and (ii) 4,939,795 shares of Common Stock issuable upon exercise of options held by Dr. Li within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Exchange Act.

As of September 30, 2026, Zhiqing Zhou may be deemed to beneficially own approximately 5.5% of the shares of Common Stock outstanding. The foregoing percentage is based on the sum of (i) 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026 and (ii) 50,564 shares of Common Stock issuable upon exercise of options held by Mr. Zhou within 60 days of September 30, 2026, which shares have been added to the total shares of Common Stock outstanding pursuant to Rule 13d-3(d)(1)(i) under the Exchange Act.

As of September 30, 2026, the Titanium Trust may be deemed to beneficially own approximately 5.5% of the shares of Common Stock outstanding. The foregoing percentage is based on 107,255,963 shares of Common Stock issued and outstanding as of September 30, 2026.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Zhen Li - 4,939,795.00
Zhiqing Zhou - 50,564.00
Titanium Trust - 0.00</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Zhen Li - 5,861,199.00
Zhiqing Zhou - 5,861,199.00
Titanium Trust - 5,861,199.00</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Zhen Li - 4,939,795.00
Zhiqing Zhou - 50,564.00
Titanium Trust - 0.00</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Zhen Li - 5,861,199.00
Zhiqing Zhou - 5,861,199.00
Titanium Trust - 5,861,199.00</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <exhibitInfo>Joint Filing Agreement</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Zhen Li</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhen Li</signature>
        <title>Zhen Li</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Zhiqing Zhou</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhiqing Zhou</signature>
        <title>Zhiqing Zhou</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Zhen Li and Zhiqing Zhou, as Co-Trustees of the Titanium Boulder Irrevocable Trust dated July 11, 2020</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhen Li</signature>
        <title>Trustee</title>
        <date>11/16/2026</date>
      </signatureDetails>
      <signatureDetails>
        <signature>/s/ Zhiqing Zhou</signature>
        <title>Trustee</title>
        <date>11/16/2026</date>
      </signatureDetails>
    </signatureInformation>
  </formData>

</edgarSubmission>
